2023
Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinoma
2022
Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery
Bakkila BF, Kerekes D, Nunez-Smith M, Billingsley KG, Ahuja N, Wang K, Oladele C, Johnson CH, Khan SA. Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery. JAMA Network Open 2022, 5: e225664. PMID: 35377425, PMCID: PMC8980937, DOI: 10.1001/jamanetworkopen.2022.5664.Peer-Reviewed Original ResearchConceptsGastrointestinal tract cancerNegative resection marginsTract cancerNegative surgical marginsBlack patientsAdequate lymphadenectomyWhite patientsQuality of careRacial disparitiesSurgical resectionResection marginsSurgical marginsSurgical careNational Cancer DatabaseRetrospective cohort studySite of cancerLonger median survivalHealth careStandard of careCommon age rangeSignificant racial disparitiesAdjuvant chemotherapyBiliary resectionAdjuvant therapyAdult patients
2019
Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival
Uhlig J, Sellers CM, Khan SA, Cha C, Kim HS. Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival. Surgical Oncology 2019, 31: 111-118. PMID: 31654956, DOI: 10.1016/j.suronc.2019.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCombined Modality TherapyDatabases, FactualFemaleFollow-Up StudiesHepatectomyHospitals, High-VolumeHospitals, Low-VolumeHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedPractice Patterns, Physicians'PrognosisRetrospective StudiesSurvival RateConceptsOverall survivalHepatocellular carcinomaAcademic centersHospital volumePatient survivalInterventional oncologyYoung African American patientsHigh-volume academic centersMultivariable Cox regressionFirst-line treatmentLow-volume centersLonger patient survivalAfrican American patientsHCC treatment modalitiesNon-academic centersLiver transplantMultivariable adjustmentPatient demographicsSurgical resectionLine treatmentCox regressionPotential confoundersVolume centersTreatment modalitiesAmerican patients
2018
Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma
Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. Journal Of Gastrointestinal Oncology 2018, 9: 517-526. PMID: 29998017, PMCID: PMC6006033, DOI: 10.21037/jgo.2018.03.05.Peer-Reviewed Original ResearchPost-operative chemoradiationPeri-operative chemotherapyNode-positive gastric cancerAdjuvant therapyPositive gastric cancerGastric adenocarcinomaAdjuvant chemotherapyGastric cancerCurative-intent gastrectomyNational Cancer DatabasePercentage of patientsThird of patientsMean survival timeMultimodality careCurative gastrectomyOverall survivalSurgical resectionCancer outcomesCancer DatabasePoor survivalClinical impactLong-term effectsRadiation therapySurvival advantageSurvival time
2016
Management of Small Nonfunctional Pancreatic Neuroendocrine Tumors
Grisotti G, Khan S. Management of Small Nonfunctional Pancreatic Neuroendocrine Tumors. Difficult Decisions In Surgery: An Evidence-Based Approach 2016, 641-653. DOI: 10.1007/978-3-319-27365-5_56.Peer-Reviewed Original ResearchNonfunctional pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsSmall Nonfunctional Pancreatic Neuroendocrine TumorsNeuroendocrine tumorsSmall pancreatic neuroendocrine tumorsType 1Multiple endocrine neoplasia type 1Von Hippel-Lindau diseaseRole of surgeryFuture prospective studiesStandard of careHippel-Lindau diseaseNeurofibromatosis type 1Selective treatment approachSurgical resectionProspective studyNonsurgical approachHepatopancreaticobiliary surgeryMalignant potentialPancreatic tumorsPNET diagnosisSmall tumorsTuberous sclerosisCancer susceptibility syndromeTreatment approaches
2012
Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs
Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich J, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR. Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs. PLOS ONE 2012, 7: e50141. PMID: 23251360, PMCID: PMC3518475, DOI: 10.1371/journal.pone.0050141.Peer-Reviewed Original ResearchConceptsMetastatic progressionWidespread metastatic diseaseLower ratesPolymetastatic progressionCurative intentInitial metastasisMetastatic diseaseSurgical resectionMetastasis samplesLimited progressionPatientsDistinct entityProgressionLatter groupRecurrenceMetastasisHigh rateIndependent validation datasetExpression patternsOligometastasesResectionMicroRNAsRadiotherapyLungValidation dataset